January 15, 2010 – 7:15 pm
by Chris
Yes, the Pharma Blog Week in Review is back. I had to take a break from it over the holidays; I even became so silent on Twitter that I had a few folks ask me if I was all right. But I knew I’d get back into the swing of things in the new year.
And [...]
Posted in
Uncategorized |
No Comments »
November 6, 2009 – 5:35 pm
by Chris
It’s a mixed bag this week in pharma industry news (much like that sack of your kids hauled home from their trick-or-treating, for every KitKat, there’s a bag of candy corn). Some of the notable items: Johnson & Johnson announced the company would be reducing its headcount by 7% (and Eli Lilly also [...]
Posted in
Uncategorized |
No Comments »
October 30, 2009 – 4:04 pm
by Chris
Halloween is tomorrow, but for the pharmaceutical industry, the real “party” will be November’s two-day meeting on social media use, sponsored by FDA. Everyone is hoping the hearing will yield a treat (in the form of a workable guidance on social media) and not tricks (in the form of FDA remaining inscrutable and issuing warning [...]
Posted in
Uncategorized |
No Comments »
October 23, 2009 – 3:51 pm
by Chris
This week was full and frantically busy, and I am not just talking about the three days I drove back and forth to Bridgewater, N.J., for ExL Pharma’s Digital Pharma conference (if you want the quick lowdown on what happened there, you can find the Tweets, from me and many others, under the hashtag #DigPharm). [...]
Posted in
Uncategorized |
No Comments »
October 16, 2009 – 4:31 pm
by Chris
The week ended in a big way, as Pfizer’s acquisition of Wyeth became final and FDA approved GlaxoSmithKline’s Cervarix vaccine for cervical cancer. Also, debate continued about the healthcare reform bill passed by the Senate Finance Committee last week. And fortunately for the industry, no recent bombs about ghostwriting or other scandals hit the air. [...]
Posted in
Uncategorized |
No Comments »
October 9, 2009 – 5:29 pm
by Chris
Now that I’m back in the office from my Boston vacation (and a very interesting visit last Monday with Jeff Porter, Tim Wright, and Mark Fishman of Novartis Institutes for Biomedical Research, which I will be writing about in January’s R&D Directions), I have some stuff to catch up on. Abbott is buying Solvay’s pharmaceutical [...]
Posted in
Uncategorized |
No Comments »
